drugset / Trial / NCT01937312
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
Timeline
- Start
- 2013-10
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIMBRINZA | Unknown | — | Other |
| Background | Bimatoprost | Other / unclassified | — | Other |
| Background | Latanoprost | Small molecule | — | Other |
| Background | Travoprost | Other / unclassified | — | Other |